NIH $20 Million Transplant Grant Aims at Better Drugs and Long-term Organ ... HealthNewsDigest.com Although belatacept avoids some of the toxicity of earlier transplant drugs, it is associated with higher rates of reversible acute rejection. And because it is a lifelong therapy, it still includes risks associated with a compromised immune system ... |
